InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector – Yahoo Finance

Share Article

CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCV

Expands the Company’s rare cannabinoid product portfolio, which also includes cannabichromene (CBC)
Strengthens leadership position in commercial scale production of high demand rare cannabinoids

VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid cannabicitran (CBT) into the health and wellness sector. CBT is the first of several new product launches planned for the first half of 2022.
InMed’s subsidiary, BayMedica, has received initial purchase orders and has commenced commercial sales of the ultra-rare cannabinoid CBT. CBT is the second rare cannabinoid to be launched by BayMedica, which also sells CBC wholesale as a raw ingredient to the health and wellness sector. Additionally, commercial scale production of cannabidivarin (CBDV) is underway, with tetrahydrocannabivarin (THCV) production scheduled to follow shortly thereafter. The Company expects to produce over 100kg of CBDV and THCV in the coming months to meet anticipated initial demand.
“We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors,” stated Shane Johnson, SVP and General Manager of BayMedica. “The launch of CBT further demonstrates our ability to produce rare cannabinoids at commercial scale, an achievement that very few companies have been able to accomplish. We are pleased with initial demand and we expect to grow sales over the coming quarters as we continue to expand our product portfolio of rare cannabinoids.”
Increasing demand for rare cannabinoids
This emerging market is expected to grow significantly due to the increasing awareness of the potential benefits of cannabinoid-based products. According to the December 2021 Grand View Research report, the retail market for rare cannabinoids is expected to reach US$26 billion by 2028 with a forecasted compounded annual growth rate (CAGR) of >20% during the same period.
With the availability of these rare cannabinoids at commercial scale, product manufacturers and consumer brands now have the ability to deliver differentiated products, including augmenting existing CBD-based products, to consumers in the health and wellness marketplace.
InMed / BayMedica commercial advantage
With flexibility across multiple manufacturing approaches, and its ability to scale up to meet market demand, InMed is well positioned to take advantage of this rapidly growing industry. The Company’s proprietary processes ensure the production of rare cannabinoids with the quality, consistency and purity required for each target market.
BayMedica manufactures rare cannabinoids through proprietary synthetic methods that ensure reproducible quality and purity. Its products are produced under food-grade GMP standards, are bioidentical to plant derived compounds and certified by 3rd party laboratories. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications including supplements, nutraceuticals, cosmetics and animal health.
For more information on how to purchase CBT and other rare cannabinoids, please reach out to the BayMedica sales team at:
About InMed: InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit and
Investor Contact:
Colin Clancy
Senior Director, Investor Relations
T: +1.604.416.0999
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: launching CBT into the health and wellness sector, launching CBDV and THCV in the coming months and producing over 100kg of CBDV and THCV in the coming months; having at least four rare cannabinoids available for the health and wellness market by midyear 2022 and growing sales over future quarters; being well positioned to take advantage of the market for rare cannabinoids utilizing the Company’s industry flexibility manufacturing approaches and its ability to produce rare cannabinoids at commercial scale; producing rare cannabinoids with the quality, consistency and purity needed for their target market sectors; the potential for rare cannabinoids to treat various diseases; being a global leader in the research, development, manufacturing and development of rare cannabinoids; and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The tech-heavy Nasdaq took off like a rocket this morning, and took semiconductor stock Nvidia (NASDAQ: NVDA) along for the ride. Just after noon ET, however, the rally started to sputter, and by the time trading for the day was done, not only had the Nasdaq given up all its gains, but Nvidia stock closed down 3.7% for the day. In the case of the Nasdaq as a whole, I fear that investors may have jumped the gun, presuming that after the Nasdaq met the definition for a stock market correction (down 10% from its high), the light would turn green for tech stocks to resume marching higher again.
As earnings season ramps up, Netflix kicked the reporting period off for big tech when it unveiled its fourth quarter results after the bell on Thursday. Here were the main metrics from Netflix's report, compared to consensus estimates compiled by Bloomberg.
Charles Schwab Chief Global Investment Strategist Jeffrey Kleintop joins Yahoo Finance Live to discuss the outlook for the stock market.
Peloton shares get crushed on reports of a production halt.
CFA and owner of Portia Capital Management Michelle Connell joins Yahoo Finance Live to discuss Big Tech, energy and financial sector fund data, commodity futures, and Fed policy makers expecting three interest rate hikes in 2022.
U.S. stocks struggled for direction Thursday afternoon after staging a comeback from a turbulent previous session as investors weighed a series of upbeat earnings and a fresh read on weekly jobless claims out of Washington.
Santosh Rao, Head of Research at Manhattan Venture Partners, joins Yahoo Finance Live to discuss Netflix's fourth quarter earnings, the need to gain more subscribers, and competition in the streaming space.
Though crashes and corrections are inevitable, they're also an ideal opportunity to buy great stocks at a discount.
The yield-sensitive Nasdaq Composite Index on Wednesday logs its first close in correction territory since March. Here's what history says happens next.
(Bloomberg) — Most Read from BloombergEarly Omicron Breakthroughs Show mRNA Vaccines’ WeaknessWhy Some Vaccinated People Resist Omicron and Others Don’tThailand to Resume Quarantine-Free Tourism as Covid EasesBiden Expects Russia to ‘Move In’ on Ukraine; Warns of SanctionsOmicron Is a Bigger Risk for the Young, Medical Data ShowsJeremy Grantham, the famed investor who for decades has been calling market bubbles, said the historic collapse in stocks he predicted a year ago is underway and even i
A report in a German trade publication has interesting implications for the Chinese EV maker.
Digital World Acquisition (NASDAQ: DWAC) stock has seen some volatile swings in this week's trading, but it's back to posting big gains today. The Trump-affiliated special purpose acquisition company's (SPAC) share price was up roughly 5.2% as of 2:30 p.m. ET Thursday. While there isn't any fresh news pertaining to Digital World Acquisition, the stock is getting a boost from today's market rally.
Rivian investment gains to increase Ford's book value
After some big sell-offs, the market is rallying today, and Palantir (NYSE: PLTR) is getting a boost from the momentum. The data analytics specialist's share price was up roughly 5.7% as of noon ET on Thursday. In the absence of any fresh, business-specific news, Palantir stock has frequently made outsize moves in conjunction with the market's shifting appetite for growth-dependent technology companies.
Affirm and its "buy now, pay later" rivals allow consumers to pay for items in scheduled instalments, instead of using a traditional credit card. Credit card companies like Mastercard and Visa make money by charging their customers compounding interest and late fees. For 0% financing, Affirm makes money by charging merchants fees to use its services; those shops pay up in hopes that Affirm's flexible payment options will encourage customers to buy from them.
Green energy stocks are among today's bigger winners, with fuel cell leaders Plug Power (NASDAQ: PLUG) and Bloom Energy (NYSE: BE) gaining 8.6% and 6%, respectively. Also moving higher is solar panel microinverter maker Enphase Energy (NASDAQ: ENPH), scoring a 5.1% gain as of 10:10 a.m. ET. This morning, you can't throw a rock on Wall Street without hitting one banker or another that is cutting price targets on renewable energy stocks.
Select analysts and investment banks see "high" return potential for these cannabis stocks.
Intuitive Surgical put up a quarterly beat Thursday following a strong preannouncement. But ISRG stock fell on bearish Covid commentary.
Shares of TaskUs (NASDAQ: TASK) fell sharply on Thursday after the release of what's known as a short report. Spruce Point Capital Management believes TaskUs stock has 25% to 50% downside. Putting their money where their mouth is, Spruce Point Capital is short shares of TaskUs, meaning it will profit if the stock goes down.
SoFi Technologies Inc. shares are soaring for the second-straight day on heavy volume as optimism continues to build for the company's banking ambitions.


You might also like

Surviving 2nd wave of corona

Surviving The 2nd Wave of Corona

‘This too shall pass away’ this famous Persian adage seems to be defeating us again and again in the case of COVID-19. Despite every effort